Bausch Health Companies Inc. - BHC Earnings per share for the last 12 months

Public company logo of Bausch Health Companies Inc. (BHC)

Bausch Health Companies (BHC) generates revenue from the sale of ophthalmology and gastroenterology products to various patient categories. Leveraging a powerful portfolio of Salix and Bausch + Lomb brands, the holding company allocates profits toward debt repayment, although massive debt continues to constrain growth. The current EPS TTM YoY growth rate on the GURU.Markets dynamic chart reflects the impact of borrowing costs, with the metric currently standing at -330.80.

BHC Bausch Health Companies Inc.: Earnings per share for the last twelve months in the range 02/11/2024 - 11/17/2026

Bausch Health Companies - analytical breakdowns and key metrics (BHC)

- share price and expert price forecast:
Fundamental company valuation:BHC - Valeant Pharmaceuticals
Signature product of Bausch Health Corp

Production automation at Bausch Health Companies (BHC) optimizes costs, yet the efficiency of R&D and clinical trial investments translates directly into earnings per share dynamics. Analyzing the historical percentage growth of EPS YoY (TTM) allows for an assessment of the annual change in net income over 12 months, where sharp deviations in the curve signal a risk of declining solvency for the company despite a formally low asset valuation.